… death among patients with mild-to-moderate COVID-19 who are at risk for severe disease
and is … antiviral treatments when indicated to prevent morbidity and mortality from COVID-19. …

… As polypharmacy is frequent in patients at risk of severe COVID-19, oral antiviral treatment
of early-stage COVID-19 poses a risk of significant DDI in the target groups. DDI may result in …

… current knowledge on the antiviral treatment of COVID-19. Investigated antivirals for SARS-…
PF-07304814 (IV) and PF-07321332 (oral) entered phase 1 clinical trials last September in …

… by many countries for the treatment of coronavirus disease 2019 (Covid-19). However, the …
oral antiviral agent with potent activity against severe acute respiratory syndrome coronavirus …

… the approval of two oral antiviral treatments — molnupiravir … antivirals for seven virus
families. Hall says this gives him hope that antiviral research will continue even as the COVID-19 …

… Overall, small molecules tend to be more accessible than biologics due to stability, oral …
to be considered when developing antivirals for the treatment of COVID-19. The propensity of …

… is to enlighten the researchers working on COVID-19 about the discovery, recent … orally
active and directly acting antiviral interventional drug. Its efficacy and tolerability in COVID-19 …

… and future oral antiviral … antivirals may address some of these barriers; however, health
systems around the world should be equipped to receive and administer COVID-19 oral antivirals…

… oral antiviral drugs for COVID-19 … oral antiviral drugs that can be administered in the
community at an early stage of SARS-CoV-2 infection is now a priority in the control of COVID-19 …

… novel oral antiviral agent can improve short-term COVID-19 … nonhospitalized adult patients
with COVID-19 between March 1, … period following a diagnosis of COVID-19. Two cohorts of …